210
Participants
Start Date
March 14, 2018
Primary Completion Date
January 15, 2019
Study Completion Date
April 18, 2019
Humalog Mix25
Subcutaneus injections Humalog® Mix 25 twice daily during 4 weeks of glucose-level based dose titration, 24 weeks of treatment with stable doses
Insulin Lispro Biphasic 25
"Subcutaneus injections Insulin Lispro Biphasic 25 (Geropharm) twice daily during 4 weeks of glucose-level based dose titration, 24 weeks of treatment with stable doses"
Railway Clinical Hospital N.A. Semashko, Moscow
Endocrinology Research Centre (Moscow), Moscow
Moscow Endocrinological Dispensary, Moscow
V.A. Baranov Republic Hospital, Petrozavodsk
City Polyclinic № 77, Saint Petersburg
City Hospital № 2, Saint Petersburg
City Polyclinic № 117, Saint Petersburg
City Polyclinic № 17, Saint Petersburg
Institute of Medical Research, Saint Petersburg
Research Center Eco-Safety, Saint Petersburg
City Hospital №40, Saint Petersburg
Pokrovskaya Municipal Hospital, Saint Petersburg
Rostov State Medical University, Rostov-on-Don
Clinical City Hospital № 9, Saratov
Diabetes Center, Samara
Chelyabinsk Railway Clinical Hospital, Chelyabinsk
Nizhny Novgorod Regional Clinical Hospital, Nizhny Novgorod
Siberian State Medical University, Tomsk
Lead Sponsor
Geropharm
INDUSTRY